Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vanadium compounds as anti-angiogenic agents

a technology of vanadium compounds and anti-angiogenic agents, which is applied in the direction of biocide, heavy metal active ingredients, drug compositions, etc., can solve the problem of 30%-50% incidence of coronary artery restenosis, and achieve the effect of inhibiting angiogenesis

Inactive Publication Date: 2006-08-17
PARKER HUGHES INST
View PDF8 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although acute complications of PTCA have markedly declined with optimized use of anticoagulants, antispasmodic agents, and intravascular stents, the incidence of coronary artery restenosis has remained at 30%-50% and represents the major obstacle to a more successful outcome of PTCA (Landzberg, et. al., 1997, Prog.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vanadium compounds as anti-angiogenic agents
  • Vanadium compounds as anti-angiogenic agents
  • Vanadium compounds as anti-angiogenic agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Vanadium Compounds

[0100] Vanadium compounds useful in the invention may be prepared by known methods, as described, for example, in published PCT Applications WO99 / 36063; WO 00 / 27389; and WO 00 / 35930. For example, VDC (VCp2Cl2) and. [VCp2(acac)](CF3SO3); (VDacac) were prepared by following literature procedures (Wilkinson et al., J. Am. Chem. Soc., 76: 4281-4284, 1954; Doyle et al., Inorg. Chem., 7: 2479-2484, 1968) and purity was confirmed by 1H NMR, IR spectroscopy, and elemental analysis.

example 2

Inhibition of Angiogenesis

[0101] The present example illustrates that vanadium compounds such as [VCp2(acac)](CF3SO3) are effective inhibitors of angiogenesis.

Chick Embryo Chorioallantoic (CAM) Assay

[0102] Inhibition of embryonic angiogenesis was determined using a bioassay system involving CAMs of growing chick embryos, as previously described (Nguyen et al, Microvascular Research, 47:31, 1994; Auerbach et al, Developmental Biology, 41:391, 1974). Fertilized white Leghorn chicken eggs were received at day 3 of incubation from the University of Minnesota Poultry Research Center, St. Paul, Minn. The following procedures took place in a sterile laminar flow hood. The eggs were wiped down with 70% isoprpyl alcohol and allowed to air dry. The eggs were wiped with Betadine and placed in a horizontal position for approximately 5 minutes and allowed to dry. The eggs were cracked and placed into sterile 100×20 mm2 Petri dishes (Fischer, Itasca, Ill.) and transferred to a 37° C. humidifi...

example 3

Inhibition of Mitosis

[0106] This example illustrates that the vanadium compound [VCp2(acac)](CF3SO3) is an effective inhibitor of embryonic development of Zebra fish, and in particular, is a potent inhibitor of mitosis.

Zebra Fish and Embryos

[0107] The adult wild type ZF were maintained generally according to the “Zebrafish Book” recommendations (Westerfield, The Zebrafish Book, 1993, 2d Edition Univ. of Oregon Press, Eugene). Males and females were kept in 10 Gallon tanks (70 fish per tank) with a constant slow flow of conditioned water at 26° C. and a controlled 14 hour day / 10 hour night cycle. Adult fish were fed twice a day with live brine shrimp (Ocean Star International, Snowville, Utah) and each group of fish was bred once in two weeks. The embryos were obtained through (a) natural spawning at 28.5° C. in the breeding tanks with a netted false bottom or (b) fertilization in vitro using eggs and milt collected from the mature females and males anesthetized with Tricaine (Si...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
inner path lengthaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

Vanadium compounds for inhibiting angiogenesis useful for treating or preventing diabetic retinopathy, hemangiomas, cancers with abnormal blood vessel supply, restenosis following vascular injury, and the like.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application is a divisional application of U.S. patent application Ser. No. 09 / 713,780, filed on Nov. 15, 2000, which application is hereby incorporated by reference in its entirety.BACKGROUND OF THE INVENTION [0002] Tissue growth is intimately associated with blood supply. Non-vascularized tissue is limited in size, often being smaller than one to two millimeters in diameter or thickness. Therefore, inhibiting blood supply to tissue represents one target point for limiting tissue growth and possibly tissue viability. [0003] The ability to inhibit blood supply has been shown to play a pivotal role in the progression, invasive and metastatic growth of malignant tumors (Folman, Nat Med, 1:27, 1995; Folkman et al, Science, 235:442, 1985; Gimbrane et al, J Exp Med, 136:261, 1972). Further, inhibition of angiogenesis new vessel formation), has been shown to result in tumor dormancy or regression and to prevent metastasis (Folkman, Ann Su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/555A61K31/28A61K33/24
CPCA61K31/28A61K31/555A61K33/24Y10S514/912Y10S514/866Y10S514/863Y10S514/908Y10S514/824Y10S514/822Y10S514/883Y10S514/954
Inventor UCKUN, FATIH M.
Owner PARKER HUGHES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com